All In Biotech

NDA 214511 · Lumicell

Lumisight

Pegulicianine Acetate · Intravenous

NovelPriority review

CDER novel approval, Apr 17, 2024: To use as an optical imaging agent for the detection of cancerous tissue

Last checked: Nov 19, 2026Latest source record: Apr 17, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Apr 17, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1

0 Phase 3, 0 recruiting

FAERS reports

8

4 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ANAPHYLAXIS AND OTHER SERIOUS HYPERSENSITIVITY REACTIONS Serious hypersensitivity reactions, including anaphylaxis, can occur during or following administration of LUMISIGHT. Anaphylaxis occurred in 4/726 (0.6%) of patients in clinical studies. Signs and symptoms associated with other hypersensitivity reactions included pruritus, urticaria, hypotension, lip swelling, erythema, anxiety, chest pain, cyanosis, dizziness, dyspnea, headache, hypoesthesia, hyperventilation, maculopapular rash, nausea, paresthesia, visual changes, and vomiting. Before LUMISIGHT administration, assess all patients for any history of hypersensitivity reaction to contrast media or products containing polyethylene glycol (PEG). Always have emergency resuscitation drugs, equipment, and trained personnel promptly available. Monitor all patients for hypersensitivity reactions. If a hypersensitivity reaction...

What it is approved for

From the label in effect Jan 9, 2026.

LUMISIGHT is indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. LUMISIGHT is an optical imaging agent indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. ( 1 )

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 17, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
  • LUMISIGHT · PEGULICIANINE ACETATE EQ 39MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pegulicianine" as an intervention, any sponsor and status, largest first.

All 1 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • flushing4
  • hypersensitivity3
  • paraesthesia3
  • anaphylactic shock2
  • back pain2
  • cardiac arrest2
  • cough2
  • feeling hot2
  • hyperhidrosis2
  • malaise2
  • nausea2
  • acute kidney injury1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20252
20266

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2 on PubMed

Sponsor: Lumicell

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.